Solving the mystery of NPM1 in acute myeloid leukemia
(Baylor College of Medicine) Acute myeloid leukemia (AML) cells expressing the NPM1 mutant gene are highly dependent on continued export of protein NPM1c to proliferate. This finding provides a rationale for testing nuclear export inhibitor therapeutics in NPM1-mutated AML. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 13, 2018 Category: Cancer & Oncology Source Type: news

Immunotherapy combination and chemotherapy show encouraging results in Phase II acute myeloid leukemia study
(University of Texas M. D. Anderson Cancer Center) A triple therapy combining two immune checkpoint inhibitors (ICPIs) with the standard-of-care chemotherapy, a hypomethylating agent called azacitidine, has shown promising results for treatment of relapsed or refractory acute myeloid leukemia (AML), according to findings from a Phase II study at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 13, 2018 Category: Cancer & Oncology Source Type: news

Lawyer was given just ONE WEEK to live after doctors misdiagnosed her leukaemia as a gum infection
Jenna Ostrowski, 34, from Birmingham, was diagnosed with acute myeloid leukaemia and told her survival chances were slim unless she started treatment immediately. (Source: the Mail online | Health)
Source: the Mail online | Health - November 12, 2018 Category: Consumer Health News Source Type: news

IHC Markers of Megakaryocytic Differentiation in AMKL IHC Markers of Megakaryocytic Differentiation in AMKL
This study compared relative sensitivities of three commonly used stains for markers of megakaryocytic differentiation in diagnosis of acute megakaryoblastic leukemia.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 12, 2018 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Cancer stem cells get energy from protein, and it's proving to be their Achilles' heel
(University of Colorado Anschutz Medical Campus) CU Cancer Center study shows that cancer stem cells switch from metabolizing sugar to metabolizing protein. Clinical trial based on this observation may revolutionize care for older adults with acute myeloid leukemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 12, 2018 Category: International Medicine & Public Health Source Type: news

Combination chemotherapy and immunotherapy effective in Phase II leukemia study
(University of Texas M. D. Anderson Cancer Center) A combination of the standard-of-care chemotherapy drug known as azacitidine, with nivolumab, an immune checkpoint inhibitor, demonstrated an encouraging response rate and overall survival in patients with relapsed or refractory acute myeloid leukemia (AML) according to findings from a Phase II study at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 8, 2018 Category: Cancer & Oncology Source Type: news

EMA Validates and Grants Accelerated Assessment of Marketing Authorization Application for Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Application based on results of pivotal phase 3 QuANTUM-R study of quizartinib in patients with relapsed/refractory FLT3-ITD AML Quizartinib is the first FLT3 inhibitor to demonstrate a survival benefit in a randomized phase 3 study in patients with rel... Biopharmaceuticals, Oncology, Regulatory Daiichi Sankyo, quizartinib, acute myeloid leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 5, 2018 Category: Pharmaceuticals Source Type: news

Amgen To Present New Data Showcasing Extensive Portfolio And Exciting Early Oncology Pipeline At ASH 2018
First-in-Human Data Evaluating AMG 420 in Multiple Myeloma and AMG 330 in Acute Myeloid Leukemia Underscore Potential of BiTE® Immunotherapy Platform Across Hematologic Malignancies BLINCYTO® (blinatumomab) Long-Term Data Demonstrate Benefits of Achieving Complete MRD Response in Adult Patients With Acute Lymphoblastic Leukemia and Reinforce BiTE® Proof-of-Concept Data From Multiple Myeloma Research Foundation CoMMpass Trial of KYPROLIS® (carfilzomib) in Newly Diagnosed Multiple Myeloma Patients to be Presented at ASH THOUSAND OAKS, Calif., Nov. 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today ann...
Source: Amgen News Release - November 1, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Low-fat diet increases cancer survival rate in mice, study finds
Something as simple as a change in diet can potentially help to increase the cancer survival rate of obese children with acute lymphoblastic leukemia, the most common childhood cancer, according to a new study by UCLA scientists.The research team, led by Dr. Steven Mittelman, chief of pediatric endocrinology at  UCLA Mattel Children ’s Hospital and member of the  UCLA Jonsson Comprehensive Cancer Center, administered the chemotherapy drug vincristine to obese and non-obese mice with leukemia. Researchers discovered that if they switched the obese mice from a high-fat to a low-fat diet immediately befor...
Source: UCLA Newsroom: Health Sciences - November 1, 2018 Category: Universities & Medical Training Source Type: news

Why Do Some AML Patients Relapse After Stem Cell Transplant? Why Do Some AML Patients Relapse After Stem Cell Transplant?
Stem cell transplants can be curative. A new study shows that patients with acute myeloid leukemia who relapse after transplant show dysregulation in genes associated with adaptive and innate immunity.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 1, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

High hospital costs for acute lymphoblastic leukaemia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2018 Category: Drugs & Pharmacology Source Type: news

Two-cells-in-one combo therapy could bolster leukemia treatment
(UCLA Samueli School of Engineering) A cancer therapy based on fusing two types of cells into a single unit shows promise in strengthening existing treatments for acute myeloid leukemia. The approach joins blood platelets that carry cancer drugs with stem cells that guide the platelets into bone marrow where leukemia begins. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 31, 2018 Category: Cancer & Oncology Source Type: news

Low-fat diet increases cancer survival rate in mice, study finds
(University of California - Los Angeles Health Sciences) Something as simple as a change in diet can potentially help to increase the cancer survival rate of obese children with acute lymphoblastic leukemia, the most common childhood cancer, according to a new study by UCLA scientists. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 31, 2018 Category: Cancer & Oncology Source Type: news

Two-cells-in-one combo could be platform to bolster leukemia treatment
Researchers led by a UCLA bioengineer have developed a therapy — based on two types of cells joined into a single unit — that could help strengthen existing treatments for acute myeloid leukemia. One of the cells is a blood platelet that carries a drug that attacks cancer cells; the other is a stem cell that guides the platelet into bone marrow, the spongy tissue inside bone where new blood cells are made and where leukemia begins. The researchers found that when injected into mice that had acute myeloid leukemia, the combination therapy halted the disease from developing any further. Of the mice that rece...
Source: UCLA Newsroom: Health Sciences - October 29, 2018 Category: Universities & Medical Training Source Type: news

Birth Weight and Risk of Childhood ALL Birth Weight and Risk of Childhood ALL
This study confirms a previously reported association between high birth weight and the risk of developing childhood acute lymphoblastic leukemia. How might this relate to ethnicity and maternal diet?Southern Medical Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 26, 2018 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Journal Article Source Type: news

Medical News Today: Acute myeloid leukemia: New treatment overcomes chemo resistance
A treatment that alters gene expression overcame chemotherapy resistance and resulted in complete remission in a mouse model of acute myeloid leukemia. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 24, 2018 Category: Consumer Health News Tags: Leukemia Source Type: news

The Src family kinase Fgr is a transforming oncoprotein that functions independently of SH3-SH2 domain regulation
Fgr is a member of the Src family of nonreceptor tyrosine kinases, which are overexpressed and constitutively active in many human cancers. Fgr expression is restricted to myeloid hematopoietic cells and is markedly increased in a subset of bone marrow samples from patients with acute myeloid leukemia (AML). Here, we investigated the oncogenic potential of Fgr using Rat-2 fibroblasts that do not express the kinase. Expression of either wild-type or regulatory tail-mutant constructs of Fgr promoted cellular transformation (inferred from colony formation in soft agar), which was accompanied by phosphorylation of the Fgr acti...
Source: Signal Transduction Knowledge Environment - October 23, 2018 Category: Science Authors: Shen, K., Moroco, J. A., Patel, R. K., Shi, H., Engen, J. R., Dorman, H. R., Smithgall, T. E. Tags: STKE Research Articles Source Type: news

New drug combination destroys chemo-resistant blood cancer
(The Ottawa Hospital) Researchers from The Ottawa Hospital and the University of Ottawa have developed a promising targeted strategy to treat chemotherapy-resistant acute myeloid leukemia (AML) and a diagnostic test to determine which AML patients would most likely benefit from this treatment. In a mouse model, the experimental treatment eliminated all signs of disease (complete remission) in 100 percent of animals, while those that received the standard treatment all died. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 22, 2018 Category: International Medicine & Public Health Source Type: news

Better treatments for acute myeloid leukemia sought with largest dataset
Researchers have put together the largest dataset of acute myeloid leukemia, featuring 672 samples from 562 patients. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 17, 2018 Category: Consumer Health News Source Type: news

OHSU-led effort results in largest cancer dataset of its kind
(Oregon Health& Science University) After more than five years and 672 patient samples, an OHSU research team has published the largest cancer dataset of its kind for a form of leukemia. The study, 'Functional Genomic Landscape of Acute Myeloid Leukemia,' published today in Nature. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 17, 2018 Category: Cancer & Oncology Source Type: news

Vast leukemia dataset could help researchers match therapies to patients
(Howard Hughes Medical Institute) Data on the molecular makeup and drug sensitivity of hundreds of patient samples could accelerate progress against the aggressive blood cancer acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 17, 2018 Category: Cancer & Oncology Source Type: news

Delving Where Few Others Have Gone, Leukemia Researchers Open New Path
A Wilmot Cancer Institute study uncovers how a single gene could be at fault in acute myeloid leukemia (AML), one of the deadliest cancers. The breakthrough gives researchers renewed hope that a gene-targeted therapy could improve AML survival rates, which have not budged in recent years. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - October 15, 2018 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news

Breast cancer drug may also work against form of leukemia
A new drug used for advanced breast cancer can also work effectively to treat acute myeloid leukemia, according to a study with mice and cells in a lab. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 9, 2018 Category: Consumer Health News Source Type: news

MD Anderson and Cyclacel Pharmaceuticals announce strategic alliance to study novel Cyclacel medicin
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Cyclacel Pharmaceuticals, Inc., today announced a three-year strategic alliance agreement that will enable clinical evaluation for safety and efficacy of three Cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and other advanced leukemias. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 4, 2018 Category: Cancer & Oncology Source Type: news

Midostaurin cost-effective option in acute myeloid leukaemia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2018 Category: Drugs & Pharmacology Source Type: news

FDA authorizes first next generation sequencing-based test to detect very low levels of remaining cancer cells in patients with acute lymphoblastic leukemia or multiple myeloma
(Source: Food and Drug Administration)
Source: Food and Drug Administration - September 28, 2018 Category: American Health Source Type: news

BLINCYTO ® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia
First Approved Oncology Treatment From Amgen Astellas Joint Venture BLINCYTO is the First-and-Only Approved CD19-Directed CD3 Bispecific T Cell Engager (BiTE®) Immunotherapy THOUSAND OAKS, Calif., Sept. 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for BLINCYTO® (blinatumomab) for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). BLINCYTO was developed in Japan by Amgen Astellas BioPharma K.K. (AABP), a joint venture between Amgen and Astellas Pharma Inc., a pharmaceuti...
Source: Amgen News Release - September 25, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Grants Fast-Track Designation to CX-01 for Acute Myeloid Leukemia
CX-01, a low-anticoagulant heparin derivative, has demonstrated good rates of complete remission, rapid platelet recovery, and no serious adverse events. (Source: CancerNetwork)
Source: CancerNetwork - September 19, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)
Second Orphan Drug Designation for OBI-3424, a novel first-in-class targeted therapy for solid and liquid tumors that express aldo-keto reductase 1c3 (AKR1C3) enzyme TAIPEI, Taiwan, Sept. 19, 2018 -- (Healthcare Sales & Marketing Network) -- OBI Pharma... Biopharmaceuticals, Oncology, FDA OBI Pharma, Acute Lymphoblastic Leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 19, 2018 Category: Pharmaceuticals Source Type: news

Children who develop ALL may have dysregulated immune function at birth
(American Association for Cancer Research) Neonatal concentrations of eight detectable inflammatory markers were significantly different in children later diagnosed with B-cell precursor acute lymphoblastic leukemia (ALL) compared with controls. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 14, 2018 Category: Cancer & Oncology Source Type: news

Double the Risk for Neurotoxicity for Hispanic Kids From ALL Rx Double the Risk for Neurotoxicity for Hispanic Kids From ALL Rx
Minority children, notably Hispanics, are more susceptible to developing methotrexate-induced neurotoxicity than non-Hispanic children during treatment for acute lymphoblastic leukemia (ALL).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 12, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Findings could improve treatment for challenging acute leukemia in children
(UNC Lineberger Comprehensive Cancer Center) Researchers from St. Jude Children's Research Hospital and the University of North Carolina Lineberger Comprehensive Cancer Center have made important discoveries that could lead to better treatment for a rare blood cancer in children that has features of both leukemia and lymphoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 12, 2018 Category: Cancer & Oncology Source Type: news

St. Jude researchers solve a central mystery of a baffling high-risk leukemia
(St. Jude Children's Research Hospital) St. Jude Children's Research Hospital investigators have unraveled the origins and identified mutations associated with a perplexing form of acute leukemia. The landmark study appears today as an advance online publication in the journal Nature and lays the foundation for more effective treatment of patients with the high-risk cancer.Their treatment is complicated because MPAL does not fit cleanly into a single diagnosis, but includes features of both acute lymphoblastic leukemia and acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 12, 2018 Category: Cancer & Oncology Source Type: news

Johns Hopkins All Children's becomes first Florida pediatric hospital to have unique leukemia therapy
Johns Hopkins All Children ’s Hospital is now the first pediatric hospital in Florida offering a cutting-edge cellular immunotherapy for advanced leukemia in children and young adults. It will be offering CAR-T Cell Gene Therapy for leukemia. Chimeric antigen receptor T-cell therapy, or CAR-T, uses a patient’s own cel ls to fight acute lymphoblastic leukemia, which affects more than 3,000 young people in the U.S. each year. This gene therapy is designed for patients who do not respond to standard… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - August 30, 2018 Category: Health Management Authors: Veronica Brezina-Smith Source Type: news

European Commission Approves BLINCYTO ® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Approval Based on Data From the Phase 1/2 '205 Study THOUSAND OAKS, Calif., Aug. 29, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved an expanded indication for BLINCYTO® (blinatumomab) as monotherapy for the treatment of pediatric patients aged one year or older with Philadelphia chromosome-negative CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL), which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation. The approval is based on ...
Source: Amgen News Release - August 29, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Novartis wins EU approval for CAR-T therapy
Novartis announced that the European Commission has approved Kymriah for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 27, 2018 Category: Pharmaceuticals Source Type: news

Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah ® (tisagenlecleucel)
Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse; and for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. (Source: World Pharma News)
Source: World Pharma News - August 27, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Connectome organization in childhood ALL and risk of delayed neurodevelopment
(Mary Ann Liebert, Inc./Genetic Engineering News) A new study provides novel insights into the cognitive effects of childhood acute lymphoblastic leukemia (ALL) and of chemotherapeutic treatment in long-term survivors of ALL. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 27, 2018 Category: Cancer & Oncology Source Type: news

For first time in 40 years, cure for acute leukemia within reach
Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now. As published today in the scientific journal Cell, Professor Yinon Ben-Neriah and his research team at the Hebrew University of Jerusalem (HU)'s Faculty of Medicine have developed a new biological drug with a cure rate of 50% for lab mice with acute leukemia. (Source: World Pharma News)
Source: World Pharma News - August 24, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

For first time in 40 years, cure for acute leukemia within reach
(The Hebrew University of Jerusalem) Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now. As published today in the scientific journal Cell, Professor Yinon Ben-Neriah and his research team at the Hebrew University of Jerusalem (HU)'s Faculty of Medicine have developed a new biological drug with a cure rate of 50 percent for lab mice with acute leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 24, 2018 Category: Cancer & Oncology Source Type: news

New Study Investigates CSF3R Mutations in Acute Myeloid Leukemia
Investigations into the CSF3R gene may help lead to better classification and precise treatment of AML. (Source: CancerNetwork)
Source: CancerNetwork - August 21, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Stress hormone linked to leukaemia progression
Cortisol is a key activator in a pathway that enables acute myeloid leukaemia cells to evade the immune system, according to a study published inCellular& Molecular Immunology.Science Daily (Source: Society for Endocrinology)
Source: Society for Endocrinology - August 15, 2018 Category: Endocrinology Source Type: news

Medical News Today: Leukemia: Do genes influence how people respond to therapy?
Some people with acute myeloid leukemia are more responsive to chemotherapy than others. Why is this, and how can this knowledge lead to better treatments? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 13, 2018 Category: Consumer Health News Tags: Leukemia Source Type: news

UCLA Health joins nationwide clinical trial for acute myeloid leukemia
UCLA Health has joined an important national clinical trial that uses genetic testing to match people who have acute myeloid leukemia, or AML, with new therapies. UCLA ’s hospital system is the first in California to offer people the opportunity to participate.The Beat AML Master Trial will evaluate a precision-based medicine approach to treating the disease; it will allow people with the disease to have immediate access to new treatments that are currently in development without having to try more traditional approaches first. The approach could streamline a patient ’s course of treatment and, ultimately, save...
Source: UCLA Newsroom: Health Sciences - August 8, 2018 Category: Universities & Medical Training Source Type: news

Comprehensive pediatric CAR T guidelines developed by MD Anderson and PALISI
(University of Texas M. D. Anderson Cancer Center) Almost one year after the US Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children with acute lymphoblastic leukemia (ALL), researchers at The University of Texas MD Anderson Cancer Center and the Pediatric Acute Lung Injury and Sepsis Investigators Network (PALISI) today published treatment guidelines for managing the treatment in the online issue of Nature Reviews Clinical Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 6, 2018 Category: Cancer & Oncology Source Type: news

MD Anderson and Jazz Pharmaceuticals collaborate to evaluate treatment options for hematol
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year collaboration agreement with a goal of evaluating therapies for multiple hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 6, 2018 Category: Cancer & Oncology Source Type: news

Ivosidenib earns FDA approval against IDH1+ acute myeloid leukemia
(University of Colorado Anschutz Medical Campus) Clinical trials at CU Cancer Center and elsewhere result in FDA approval of the drug ivosidenib for the treatment of adult patients with IDH1+ AML. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 30, 2018 Category: Biology Source Type: news

FDA Approves Tibsovo for Acute Myeloid Leukemia
MONDAY, July 23, 2018 -- Tibsovo (ivosidenib) tablets have been approved by the U.S. Food and Drug Administration to treat relapsed or refractory acute myeloid leukemia (AML) among people with a defective IDH1 gene. Tibsovo's effectiveness was... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 23, 2018 Category: Pharmaceuticals Source Type: news

TIBSOVO (ivosidenib), an IDH1 Inhibitor Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia with an IDH1 Mutation, Available for Order at Biologics, Inc.
CARY, N.C. (July 23, 2018) —Biologics, Inc., a McKesson Specialty Health oncology, neurology and complex care pharmacy services company, has been selected by Agios Pharmaceuticals, Inc. to be in the limited distribution network for TIBSOVO® (ivosidenib), an IDH1 inhibitor approved by the U.S. Food a... (Source: McKesson News)
Source: McKesson News - July 23, 2018 Category: Information Technology Source Type: news

Tibsovo Approved for Acute Myeloid Leukemia
Title: Tibsovo Approved for Acute Myeloid LeukemiaCategory: Health NewsCreated: 7/21/2018 12:00:00 AMLast Editorial Review: 7/23/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 23, 2018 Category: Cancer & Oncology Source Type: news